Indication
Hematological Disorder
3 clinical trials
6 products
Clinical trial
A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis and Essential Thrombocytopenia)Status: Active (not recruiting), Estimated PCD: 2024-10-31
Product
RuxolitinibProduct
PelabresibClinical trial
Efficacy and Safety of Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological DiseaseStatus: Recruiting, Estimated PCD: 2024-05-31
Product
HetrombopagClinical trial
Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell TransplantationStatus: Completed, Estimated PCD: 2021-12-31
Product
FoscarnetProduct
Ganciclovir